Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Elutia
ELUT
Elutia
Narrow Product Focus Will Face Regulatory Hurdles Yet Inspire Improvement
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$5.00
52.0% undervalued
intrinsic discount
24 Aug
US$2.40
1Y
-39.8%
7D
18.8%
Loading
1Y
-39.8%
7D
18.8%
Author's Valuation
US$5.0
52.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$5.0
52.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-60m
176m
2018
2020
2022
2024
2025
2026
2028
Revenue US$176.4m
Earnings US$10.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
51.27%
Biotech revenue growth rate
11.84%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.09%
Calculation
US$10.64m
Earnings '28
x
45.27x
PE Ratio '28
=
US$481.43m
Market Cap '28
US$481.43m
Market Cap '28
/
78.25m
No. shares '28
=
US$6.15
Share Price '28
US$6.15
Share Price '28
Discounted to 2025 @ 7.16% p.a.
=
US$5.00
Fair Value '25
